Dolutegravir

From Ganfyd

Jump to: navigation, search
dolutegravir

Contents

Introduction

Dolutegravir is a integrase inhibitor used for the treatment of HIV infection. In combination with abacavir and lamivudine it is superior to raltegravir in this combination[1]. This may be because its use is not always associated with resistance to raltegravir-associated resistence mutations.

Clinical Use

Indications

  • HIV infection as part of combination therapy
  • Triumeq® is a combination of dolutegravir, abacavir sulfate and lamivudine
  • Juluca® is a combination of dolutegravir and rilpivirine

Administration

oral od

Clinical Issues

Contra-indications

Cautions and Interactions

Side effects

  • Hypersensitivity
  • Insomnia
  • Headache
  • Deterioration liver function in patients co-infected with hepatitis B or C

Special advice

Pharmacology

References